• 1
    Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary: case report. Am J Obstet Gynecol 1959; 77: 197209.
  • 2
    Halperin R,Zehavi S,Langer R,Hadas E,Bukovsky I,Schneider D. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 2001; 11: 4038.
  • 3
    Bloss JD,Brady MF,Liao SY,Rocereto T,Partridge EE,Clarke-Pearson DL; Gynecologic Oncology Group Study. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma. Gynecol Oncol 2003; 89: 14854.
  • 4
    Barda G,Menczer J,Chetrit A,Lubin F,Beck D,Piura B,Glezerman M,Modan B,Sadetzki S; National Israel Ovarian Cancer Group. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 2004; 190: 103945.
  • 5
    Bloss JD,Liao SY,Buller RE,Manetta A,Berman ML,McMeekin S,Bloss LP,DiSaia PJ. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993; 50: 34751.
  • 6
    Chen LM,Yamada SD,Fu YS,Baldwin RL,Karlan BY. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003; 13: 74955.
  • 7
    Kurman RJ,Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008; 27: 15160.
  • 8
    Jarboe EA,Folkins AK,Drapkin R,Ince TA,Agoston ES,Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008; 53: 12738.
  • 9
    Kindelberger DW,Lee Y,Miron A,Hirsch MS,Feltmate C,Medeiros F,Callahan MJ,Garner EO,Gordon RW,Birch C,Berkowitz RS,Muto MG, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 1619.
  • 10
    Roffers SD,Wu XC,Johnson CH,Correa CN. Incidence of extraovarian primary cancers in the United States, 1992–1997. Cancer 2003; 97 ( Suppl 10): 26437.
  • 11
    Menczer J,Chetrit A,Barda G,Lubin F,Fishler Y,Altaras M,Levavi H,Struewing JP,Sadetzki S,Modan B. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 2003; 88: 5861.
  • 12
    Bandera CA,Muto MG,Schorge JO,Berkowitz RS,Rubin SC,Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998; 92: 596600.
  • 13
    Zeig-Owens R,Knowlton R,Gershman ST,Howe HL. CINA highlights of cancer incidence and mortality in the United States and Canada, 2000–2004. Springfield, IL: North American Association of Central Cancer Registries, 2007.
  • 14
    Fritz A,Percy C,Jack A,Shanmugaratnam K,Sobin L,Parkin DM,Whelan S. International classification of disease for oncology, 3rd edn. Geneva, Switzerland: World Health Organization, 2000.
  • 15
    ShambaughEM,WeissMA, eds. Summary staging guide (SSS1977). Cancer Surveillance Epidemiology and End Results Reporting, SEER Program. Bethesda, MD: NIH (Pub. No. 01-2313), 2001.
  • 16
    YoungJLJr,RoffersSD,ReisLAG,FritzAG,HurlbutAA, eds. SEER summary staging manual—2000 codes and coding instructions (SSS2000). Bethesda, MD: National Cancer Institute, NIH (Pub. No. 01-4969), 2001.
  • 17
    US Census Bureau. United States Census 2000. Available at: Updated July 2008.
  • 18
    Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 6.4.4. Bethesda, MD: National Cancer Institute, 2008. Available at:
  • 19
    Fay MP,Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997; 16: 791801.
  • 20
    Fay MP. Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theor Meth 1999; 28: 214160.
  • 21
    Fay MP,Tiwari RC,Feuer EJ,Zou Z. Estimating average annual percent change for disease rates without assuming constant change. Biometrics 2006; 62: 84754.
  • 22
    Goodman MT,Howe HL,Tung KH,Hotes J,Miller BA,Coughlin SS,Chen VW. Incidence of ovarian cancer by race and ethnicity in the United States, 1992–1997. Cancer 2003; 97( Suppl 10): 267685.
  • 23
    Muto MG,Welch WR,Mok SC,Bandera CA,Fishbaugh PM,Tsao SW,Lau CC,Goodman HM,Knapp RC,Berkowitz RS. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995; 55: 4902.
  • 24
    Schorge JO,Muto MG,Welch WR,Bandera CA,Rubin SC,Bell DA,Berkowitz RS,Mok SC. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90: 8415.
  • 25
    Huang LW,Garrett AP,Schorge JO,Muto MG,Bell DA,Welch WR,Berkowitz RS,Mok SC. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol 2000; 114: 939.
  • 26
    Dalrymple JC,Bannatyne P,Russell P,Solomon HJ,Tattersall MH,Atkinson K,Carter J,Duval P,Elliott P,Friedlander M,Murray J,Coppleson M. Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 cases. Cancer 1989; 64: 11015.
  • 27
    Fromm GL,Gershenson DM,Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990; 75: 8995.
  • 28
    Killackey MA,Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993; 51: 1714.
  • 29
    Choi CH,Kim TJ,Kim WY,Ahn GH,Lee JW,Kim BG,Lee JH,Bae DS. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecol Oncol 2007; 105: 7628.
  • 30
    Eltabbakh GH,Piver MS,Natarajan N,Mettlin CJ. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998; 91: 2549.
  • 31
    Medeiros F,Muto MG,Lee Y,Elvin JA,Callahan MJ,Feltmate C,Garber JE,Cramer DW,Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 2306.
  • 32
    Goodman MT,Correa CN,Tung KH,Roffers SD,Cheng Wu X,Young JLJr,Wilkens LR,Carney ME,Howe HL. Stage at diagnosis of ovarian cancer in the United States, 1992–1997. Cancer 2003; 97: 264859.